Compare · DXCM vs NARI
DXCM vs NARI
Side-by-side comparison of DexCom Inc. (DXCM) and Inari Medical Inc. (NARI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NARI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 8.5x NARI ($3.47B).
- DXCM has hit the wire 26 times in the past 4 weeks while NARI has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 18 for NARI).
- Company
- DexCom Inc.
- Inari Medical Inc.
- Price
- $76.59+5.15%
- $79.97+0.03%
- Market cap
- $29.57B
- $3.47B
- 1M return
- +25.71%
- -
- 1Y return
- -10.56%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2020
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 18
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Inari Medical Inc.
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest NARI
- Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone
- SEC Form 15-12G filed by Inari Medical Inc.
- Director Warner Robert Keith closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Tu Thomas was granted 7,406 shares, closing all direct ownership in the company (SEC Form 4)
- Director Szyman Catherine M. closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Strange Kevin T closing all direct ownership in the company (SEC Form 4)
- Principal Accounting Officer Silva Karen closing all direct ownership in the company (SEC Form 4)
- Director Root Jonathan D closing all direct ownership in the company (SEC Form 4)
- Director Milder Donald B closing all direct ownership in the company (SEC Form 4)
- Director Mead Dana G Jr. closing all direct ownership in the company (SEC Form 4)